Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath
Advertisement
Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, is a clinical professor of hematology, of the Faculty of Medicine & Health Sciences, at the University of Nottingham (Centre for Cancer Sciences, Academic Unit of Translational Medical Sciences, School of Medicine).
Articles by Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5